Stratifying by BC subtype, the median age at diagnosis varied, with patients who were hormone receptor+/HER2+ being the youngest (53 years) and patients who were hormone receptor+/HER2– being the oldest (58 years; P < .001; Table 2). This evidence concerns the gene ERBB2 and breast cancer.